Safety and efficacy of combined intra-articular administration of vancomycin and ε-aminocaproic acid in total hip arthroplasty : a clinical study

Bone Joint J. 2025 Feb 1;107-B(2):157-163. doi: 10.1302/0301-620X.107B2.BJJ-2024-0232.R2.

Abstract

Aims: To evaluate the concurrent use of vancomycin and ε-aminocaproic acid (EACA) in primary total hip arthroplasty (THA).

Methods: In total, 120 patients undergoing unilateral primary THA were divided into three groups: Group VE received intra-articular vancomycin and EACA; Group V received only intra-articular vancomycin; and Group E received only intra-articular EACA. Blood and joint fluids were sampled postoperatively to measure the vancomycin levels using chromatography. Blood loss and kidney function were monitored.

Results: Groups E and VE had equivalent blood loss, which was less than that in Group V. Intra-articular vancomycin levels were higher in Group VE at all intervals, with similar serum levels across the groups. Acute kidney injury, ototoxicity, and allergies were not observed, nor was a difference in rates of periprosthetic joint infection.

Conclusion: Adding intra-articular EACA to vancomycin did not affect intra-articular vancomycin levels, and maintained EACA's antifibrinolytic effects.

MeSH terms

  • Adult
  • Aged
  • Aminocaproic Acid* / administration & dosage
  • Aminocaproic Acid* / adverse effects
  • Anti-Bacterial Agents* / administration & dosage
  • Anti-Bacterial Agents* / adverse effects
  • Anti-Bacterial Agents* / pharmacokinetics
  • Antifibrinolytic Agents* / administration & dosage
  • Arthroplasty, Replacement, Hip* / methods
  • Blood Loss, Surgical / prevention & control
  • Drug Therapy, Combination
  • Female
  • Humans
  • Injections, Intra-Articular
  • Male
  • Middle Aged
  • Prosthesis-Related Infections / prevention & control
  • Treatment Outcome
  • Vancomycin* / administration & dosage
  • Vancomycin* / adverse effects
  • Vancomycin* / pharmacokinetics

Substances

  • Vancomycin
  • Anti-Bacterial Agents
  • Aminocaproic Acid
  • Antifibrinolytic Agents